HALIFAX, Dec. 31 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR,
NASDAQ: MMIRF), a developer of rapid diagnostic technology and
solutions, announced today that five of the Company's rapid tests for
diseases including HIV, H.Pylori, Syphilis, and Hepatitis B and C have
been approved for sale in Jordan by that country's Food and Drug
Administration. This approval and subsequent product sales mark
MedMira's first win in the Middle East, a highly lucrative region where
the Company has numerous market development initiatives underway.
While all of the approved MedMira products are expected to see sales in
Jordan in the coming months, the initial focus will be on the Multiplo
HBV/HIV/HCV test for guest worker testing programs required at Jordan's
border entry points. Currently, testing guest workers is a long and
arduous procedure which can take up to two weeks to process and return
results. Guest workers make up a large portion of the migrant
population of the Middle East. In 2010, Jordan's Labour Ministry
carried out health tests, including HIV testing, on more than 232,000
guest workers of various nationalities entering the country.
"Jordan is a gateway to the many opportunities that MedMira and its
local market partners are pursuing in the Middle East," said Hermes
Chan, CEO, MedMira. "The opportunities for high margin sales in Jordan
and other countries of the Middle East, where healthcare systems are
quite sophisticated, combined with high volume sales in developing
regions such as Africa and Asia is the right mix of customers for
MedMira's long term growth strategy."
The approval includes MedMira's Reveal HIV, H. Pylori and Syphilis rapid
single tests as well as the Company's Multiplo tests for the
simultaneous diagnosis of HIV and/or Syphilis and the triple test for
HIV and/or Hepatitis B and/or C. These products were submitted for
evaluation and processed in a relatively short time frame with the
assistance of MedMira's local partner, multiMed Holdings Inc., a
US-based international sales and marketing firm who has built a strong
distribution platform to cultivate a network of sales offices,
servicing key markets around the world.
MedMira is a leading developer and manufacturer of flow-through rapid
diagnostics and technologies. The Company's tests provide hospitals,
labs, clinics and individuals with reliable, rapid diagnosis for
infectious diseases in minutes. MedMira diagnostics are sold under the
Reveal®, MiraWell®, MiraCare™ and Multiplo™ brands in global markets.
MedMira's rapid HIV test is the only one in the world to achieve
regulatory approvals in Canada, the United States, China and the
European Union. MedMira's corporate offices and manufacturing
facilities are located in Halifax, Nova Scotia, Canada. For more
information visit MedMira's website at www.medmira.com.
This news release contains forward-looking statements, which involve
risk and uncertainties and reflect the company's current expectation
regarding future events. Actual events could materially differ from
those projected herein and depend on a number of factors including, but
not limited to, changing market conditions, successful and timely
completion of clinical studies, uncertainties related to the regulatory
approval process, establishment of corporate alliances and other risks
detailed from time to time in the company quarterly filings.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this statement.
SOURCE MedMira Inc.
For further information: For further information: